The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Abstract
Importance: Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis and 25% of patients with amyloid transthyretin (ATTR) amyloidosis die within 24 months of diagnosis. Effective therapy exists but is ineffective if end-organ damage is severe. Objective: To provide evidence-based recommendations that could allow clinicians to diagnose this rare set of diseases earlier and enable accurate staging and counseling about prognosis. Evidence Review: A comprehensive literature search was conducted by a reference librarian with publication dates from January 1, 2000, to December 31, 2019. Key search terms included amyloid, amyloidosis, nephrotic syndrome, heart failure preserved ejection fraction, and peripheral neuropathy. Exclusion criteria included case reports, non-English-language text, and case series of fewer than 10 patients. The authors independently selected and appraised relevant literature. Findings: There was a total of 1769 studies in the final data set. Eighty-one articles were included in this review, of which 12 were randomized clinical trials of therapy that included 3074 patients, 9 were case series, and 3 were cohort studies. The incidence of AL amyloidosis is approximately 12 cases per million persons per year and there is an estimated prevalence of 30 000 to 45 000 cases in the US and European Union. The incidence of variant ATTR amyloidosis is estimated to be 0.3 cases per year per million persons with a prevalence estimate of 5.2 cases per million persons. Wild-type ATTR is estimated to have a prevalence of 155 to 191 cases per million persons. Amyloidosis should be considered in the differential diagnosis of adult nondiabetic nephrotic syndrome; heart failure with preserved ejection fraction, particularly if restrictive features are present; unexplained hepatomegaly without imaging abnormalities; peripheral neuropathy with distal sensory symptoms, such as numbness, paresthesia, and dysesthesias (although the autonomic manifestations occasionally may be the presenting feature); and monoclonal gammopathy of undetermined significance with atypical clinical features. Staging can be performed using blood testing only. Therapeutic decision-making for AL amyloidosis involves choosing between high-dose chemotherapy and stem cell transplant or bortezomib-based chemotherapy. There are 3 therapies approved by the US Food and Drug Administration for managing ATTR amyloidosis, depending on clinical phenotype. Conclusions and Relevance: All forms of amyloidosis are underdiagnosed. All forms now have approved therapies that have been demonstrated to improve either survival or disability and quality of life. The diagnosis should be considered in patients that have a multisystem disorder involving the heart, kidney, liver, or nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Gillmore, J. D., Maurer, M. S., Falk, R. H., Merlini, G., Damy, T., Dispenzieri, A., Wechalekar, A. D., Berk, J. L., Quarta, C. C., Grogan, M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.021612 · Cited by 2,081
Self-citationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationKumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Colby, C., Laumann, K., Zeldenrust, S. R., Leung, N., Dingli, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5724 · Cited by 1,137
Self-citationWechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Self-citationPalladini, G., Dispenzieri, A., Gertz, M. A., Kumar, S., Wechalekar, A., Hawkins, P. N., Schönland, S., Hegenbart, U., Comenzo, R., Kastritis, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7614 · Cited by 974
Self-citationVrana, J. A., Gamez, J. D., Madden, B. J., Theis, J. D., Bergen, H. R., & Dogan, A. (2009) · Blood · doi:10.1182/blood-2009-07-230722 · Cited by 904
A new staging system for cardiac transthyretin amyloidosis
Gillmore, J. D., Damy, T., Fontana, M., Hutchinson, M., Lachmann, H. J., Martinez-Naharro, A., Quarta, C. C., Rezk, T., Whelan, C. J., Gonzalez-Lopez, E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx589 · Cited by 776
Grogan, M., Scott, C. G., Kyle, R. A., Zeldenrust, S. R., Gertz, M. A., Lin, G., Klarich, K. W., Miller, W. L., Maleszewski, J. J., & Dispenzieri, A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.033 · Cited by 763
Self-citationRepurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Tanskanen, M., Peuralinna, T., Polvikoski, T., Notkola, I., Sulkava, R., Hardy, J., Singleton, A., Kiuru‐Enari, S., Paetau, A., Tienari, P. J., et al. (2008) · Annals of Medicine · doi:10.1080/07853890701842988 · Cited by 591
Benson, M. D., Buxbaum, J. N., Eisenberg, D. S., Merlini, G., Saraiva, M. J. M., Sekijima, Y., Sipe, J. D., & Westermark, P. (2018) · Amyloid · doi:10.1080/13506129.2018.1549825 · Cited by 566
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Self-citationHigh-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070484 · Cited by 519
Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., Basset, M., Hawkins, P., Merlini, G., & Wechalekar, A. D. (2015) · Blood · doi:10.1182/blood-2015-01-620302 · Cited by 450
Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction
Mohammed, S. F., Mirzoyev, S. A., Edwards, W. D., Dogan, A., Grogan, D. R., Dunlay, S. M., Roger, V. L., Gertz, M. A., Dispenzieri, A., Zeldenrust, S. R., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2013.11.004 · Cited by 448
Self-citationTenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release
Sperry, B. W., Reyes, B. A., Ikram, A., Donnelly, J. P., Phelan, D., Jaber, W. A., Shapiro, D., Evans, P. J., Maschke, S., Kilpatrick, S. E., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.092 · Cited by 358
Screening Panels for Detection of Monoclonal Gammopathies
Katzmann, J. A., Kyle, R. A., Benson, J., Larson, D. R., Snyder, M. R., Lust, J. A., Rajkumar, S. V., & Dispenzieri, A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.126664 · Cited by 348
Self-citationCardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment
Siddiqi, O. K., & Ruberg, F. L. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.07.004 · Cited by 333
Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
Lousada, I., Comenzo, R. L., Landau, H., Guthrie, S., & Merlini, G. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0250-0 · Cited by 269
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
Judge, D. P., Heitner, S. B., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., Selby, V. N., Jacoby, D., Hanna, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.012 · Cited by 263
Bochtler, T., Hegenbart, U., Kunz, C., Granzow, M., Benner, A., Seckinger, A., Kimmich, C., Goldschmidt, H., Ho, A. D., Hose, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4947 · Cited by 234
Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis
Quarta, C. C., Gonzalez-Lopez, E., Gilbertson, J. A., Botcher, N., Rowczenio, D., Petrie, A., Rezk, T., Youngstein, T., Mahmood, S., Sachchithanantham, S., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx047 · Cited by 227
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017) · Blood · doi:10.1182/blood-2017-01-763599 · Cited by 225
AL amyloidosis: from molecular mechanisms to targeted therapies
Merlini, G. (2017) · Hematology · doi:10.1182/asheducation-2017.1.1 · Cited by 200
Sattianayagam, P. T., Hahn, A. F., Whelan, C. J., Gibbs, S. D. J., Pinney, J. H., Stangou, A. J., Rowczenio, D., Pflugfelder, P. W., Fox, Z., Lachmann, H. J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr383 · Cited by 196
Buxbaum, J. N., & Ruberg, F. L. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.200 · Cited by 178
Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study
Ueda, M., Horibata, Y., Shono, M., Misumi, Y., Oshima, T., Su, Y., Tasaki, M., Shinriki, S., Kawahara, S., Jono, H., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.117 · Cited by 164
Liver transplantation in transthyretin amyloidosis: Issues and challenges
Carvalho, A. N., Rocha, A., & Lobato, L. C. L. (2014) · Liver Transplantation · doi:10.1002/lt.24058 · Cited by 155
Obici, L. P., Kuks, J. B. M., Buades, J., Adams, D., Suhr, O. B., Coelho, T., & Kyriakides, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000290 · Cited by 146
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing
Muchtar, E., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Dingli, D., Leung, N., Buadi, F. K., Hayman, S. R., Kapoor, P., Hwa, Y. L., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.006 · Cited by 142
Self-citationGilbertson, J. A., Theis, J. D., Vrana, J. A., Lachmann, H. J., Wechalekar, A. D., Whelan, C. J., Hawkins, P. N., Doǧan, A., & Gillmore, J. D. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202722 · Cited by 138
Muchtar, E., Dispenzieri, A. A., Leung, N., Lacy, M. Q., Buadi, F. K., Dingli, D., Grogan, M. A., Hayman, S. R., Kapoor, P., Hwa, Y. L., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0060-x · Cited by 138
Self-citationStem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
Sidiqi, M. H., Aljama, M. A., Buadi, F. K., Warsame, R. M., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Gonsalves, W. I., Kumar, S. K., Kapoor, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9554 · Cited by 127
Self-citationDevelopment of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7
Dyck, P. J. B., González‐Duarte, A., Obici, L. P., Polydefkis, M. J., Wiesman, J. F., Antonino, I., Litchy, W. J., & Dyck, P. J. B. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.116424 · Cited by 117
Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers
Kyriakou, P., Mouselimis, D., Tsarouchas, A., Rigopoulos, A. G., Bakogiannis, C., Noutsias, M., & Vassilikos, V. P. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0952-8 · Cited by 115
American Journal of Hematology
Zaja, F. F., FANIN, R., Barcellini, W., Cantoni, S., Carpenedo, M., Caparrotti, G., Carrai, V., Renzo, N. D., Santoro, C., Nicola, M. D., et al. (2006) · American Journal of Hematology · doi:10.1002/(issn)1096-8652 · Cited by 107
Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N. W. C. J., Gay, F., Hegenbart, U., Hájek, R., Zweegman, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0209-7 · Cited by 106
Thompson, C. A., Kyle, R. A., Gertz, M. A., Heit, J. A., Pruthi, R. K., & Pardanani, A. D. (2009) · American Journal of Hematology · doi:10.1002/ajh.21603 · Cited by 105
Self-citationPredictive model of response to tafamidis in hereditary ATTR polyneuropathy
Monteiro, C., Mesgarzadeh, J. S., Anselmo, J., Fernandes, J., Novais, M., Rodrigues, C., Brighty, G. J., Powers, D. L., Powers, E. T., Coelho, T., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126526 · Cited by 98
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis
Kourelis, T., Kyle, R. A., Dingli, D., Buadi, F. K., Kumar, S. K., Gertz, M. A., Lacy, M. Q., Kapoor, P., Go, R. S., Gonsalves, W. I., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.016 · Cited by 96
Self-citationA phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis
Palladini, G. O., Milani, P., Foli, A., Basset, M., Russo, F., Perlini, S., & Merlini, G. (2017) · Blood · doi:10.1182/blood-2016-12-756528 · Cited by 93
Bochtler, T., Hegenbart, U., Kunz, C., Benner, A., Kimmich, C. R., Seckinger, A., Hose, D., Goldschmidt, H., Granzow, M., Dreger, P., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676361 · Cited by 85
Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis
Geller, H. I., Singh, A., Mirto, T. M., Padera, R. F., Mitchell, R. N., Laubach, J. P., & Falk, R. H. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.09.016 · Cited by 84
Familial amyloid polyneuropathy
Adams, D., Cauquil, C., & Labeyrie, C. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000476 · Cited by 65
Hereditary transthyretin-related amyloidosis
Finsterer, J., Iglseder, S., Wanschitz, J., Topakian, R., Löscher, W. N., & Grisold, W. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.13035 · Cited by 64
Kastritis, E., Leleu, X. P., Arnulf, B., Zamagni, E., Cibeira, M. T., Kwok, F., Mollee, P. N., Hájek, R., Moreau, P., Jaccard, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.646.646 · Cited by 63
Palladini, G. O., Jaccard, A., Milani, P., Lavergne, D., Foli, A., Bender, S., Lavatelli, F., Bosoni, T., Valentini, V., Pirolini, L., et al. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-1024 · Cited by 45
Dittrich, T., Benner, A., Kimmich, C. R., Siepen, F. A. D., Veelken, K., Kristen, A. V., Bochtler, T., Katus, H. A., Müller‐Tidow, C., Hegenbart, U., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205336 · Cited by 45
Cappelli, F., Baldasseroni, S., Bergesio, F., Perlini, S., Salinaro, F., Padeletti, L., Attanà, P., Perini, A. P., Pignone, A. M., Grifoni, E., et al. (2015) · Clinical Cardiology · doi:10.1002/clc.22353 · Cited by 43
Moore, P. T., Burrage, M. K., Mackenzie, E., Law, W. P., Korczyk, D., & Mollee, P. N. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.12.017 · Cited by 32
Current Concepts of Cardiac Amyloidosis
Ritts, A. J., Cornell, R. F., Swiger, K. J., Singh, J., Goodman, S. A., & Lenihan, D. J. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.12.003 · Cited by 32
Amyloid in bone marrow smears in systemic light-chain amyloidosis
Kimmich, C. R., Schönland, S. O., Kräker, S., Andrulis, M., Ho, A. D., Mayer, G., Dittrich, T., Hundemer, M., & Hegenbart, U. (2017) · Amyloid · doi:10.1080/13506129.2017.1314959 · Cited by 30
Varga, C., & Comenzo, R. L. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0284-4 · Cited by 24
Beyond NEOD001 for systemic light-chain amyloidosis
Varga, C., Lentzsch, S., & Comenzo, R. L. (2018) · Blood · doi:10.1182/blood-2018-07-865857 · Cited by 20
Suhr, O. B., Gustavsson, S., Heldestad, V., Hörnsten, R., Lindqvist, P., Nordh, E., & Wiklund, U. (2012) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s24652 · Cited by 8
Popat, R., Dowling, E., Achhala, S., Pandit, D., Rabin, N. K., Kyriakou, C. A., Mackinnon, S., Yong, K., & Wechalekar, A. D. (2017) · British Journal of Haematology · doi:10.1111/bjh.14897 · Cited by 6
Cited by
Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis
Kumar, S., Song, K., Wang, J., Baghel, M. S., Zeng, Y., Shen, K., Zheng, J., Crane, J., Demehri, S., Gao, P., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00924-z · Cited by 16
Monoclonal Insulin Autoimmune Syndrome Successfully Treated with Plasma Cell Directed Therapy
Askeland, F. B., Frøen, H. M., Bolstad, N., Thorsby, P. M., Schjesvold, F., Wammer, A. C. P., Følling, I., & Tjønnfjord, G. E. (2025) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2024.10.005 · Cited by 2
Metadata
- Authors
- Gertz, M. A., & Dispenzieri, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-07-07
- Volume
- 324
- Issue
- 1
- Pages
- 79
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3038459712
- Cited by
- 366
- References
- 59
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.